NasdaqGS:SRPTBiotechs
Has Sarepta Therapeutics (SRPT) Fallen Below Fair Value After FDA Progress?
Sarepta Therapeutics stock is coming off a long period of weak share price performance, with a steep decline over the past three years sitting alongside a mixed valuation profile and fresh regulatory progress that could influence how investors think about what the shares are worth today.
Over the past three years, Sarepta Therapeutics has fallen 83.7%, which places the current valuation in the context of a prolonged drawdown rather than a recent rally.
The FDA’s acceptance of supplemental...